We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Screening Method Detects Chromosomal Abnormalities Associated with Autism

By LabMedica International staff writers
Posted on 29 Oct 2008
Multiplex ligation-dependent probe amplification (MLPA), a recently developed method of investigating DNA, was evaluated as a screen for chromosomal disorders commonly associated with autism spectrum disorders (ASDs).

ASDs have been increasingly associated with genetic abnormalities. More...
At the same time, many children with ASDs also have some degree of cognitive impairment. In this study, the authors used MLPA on a group of 279 children with ASD, looking for abnormalities that are known to be associated with cognitive impairment.

Professor Joseph Buxbaum from Mount Sinai School of Medicine (New York, NY, USA) led the team of scientists tasked with evaluating the use of MLPA in genetic counseling. He said, "By focusing on well-known genetic disorders, rather than assaying an individual's entire genome, MLPA allows for much more efficiency.” As additional genetic abnormalities associated with ASDs are identified, additional probes can be used in future screens. Professor Buxbaum added, "MLPA is a relatively practical, inexpensive and fast tool for screening chromosome rearrangements in autism spectrum disorders."

The scientists demonstrated the effectiveness of MLPA as a screen for known genetic disorders, and identified new genetic changes that are likely to contribute to ASD, such as novel duplications (extra copies of genetic material) in chromosomes 15 and 22, which may increase liability and/or exacerbate ASD symptoms.

Related Links:
Mount Sinai School of Medicine



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.